KR102412212B1 - 황-함유 화합물을 포함하는 마이크로입자 - Google Patents

황-함유 화합물을 포함하는 마이크로입자 Download PDF

Info

Publication number
KR102412212B1
KR102412212B1 KR1020187035476A KR20187035476A KR102412212B1 KR 102412212 B1 KR102412212 B1 KR 102412212B1 KR 1020187035476 A KR1020187035476 A KR 1020187035476A KR 20187035476 A KR20187035476 A KR 20187035476A KR 102412212 B1 KR102412212 B1 KR 102412212B1
Authority
KR
South Korea
Prior art keywords
microparticle
microparticles
cysteamine
pharmaceutical composition
ethylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187035476A
Other languages
English (en)
Korean (ko)
Other versions
KR20190016957A (ko
Inventor
데보라 오닐
Original Assignee
노바바이오틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바바이오틱스 리미티드 filed Critical 노바바이오틱스 리미티드
Publication of KR20190016957A publication Critical patent/KR20190016957A/ko
Application granted granted Critical
Publication of KR102412212B1 publication Critical patent/KR102412212B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Accessories For Mixers (AREA)
KR1020187035476A 2016-06-07 2017-06-06 황-함유 화합물을 포함하는 마이크로입자 Active KR102412212B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346969P 2016-06-07 2016-06-07
US62/346,969 2016-06-07
GBGB1609940.0A GB201609940D0 (en) 2016-06-07 2016-06-07 Microparticles
GB1609940.0 2016-06-07
PCT/GB2017/051637 WO2017212249A1 (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Publications (2)

Publication Number Publication Date
KR20190016957A KR20190016957A (ko) 2019-02-19
KR102412212B1 true KR102412212B1 (ko) 2022-06-23

Family

ID=56508202

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187035476A Active KR102412212B1 (ko) 2016-06-07 2017-06-06 황-함유 화합물을 포함하는 마이크로입자

Country Status (16)

Country Link
US (1) US11369568B2 (https=)
EP (1) EP3463325B1 (https=)
JP (1) JP7195934B2 (https=)
KR (1) KR102412212B1 (https=)
CN (1) CN109310654A (https=)
AU (1) AU2017277897B2 (https=)
BR (1) BR112018075221B1 (https=)
CA (2) CA3026743C (https=)
DK (1) DK3463325T3 (https=)
ES (1) ES2965017T3 (https=)
FI (1) FI3463325T3 (https=)
GB (1) GB201609940D0 (https=)
MX (1) MX2018014278A (https=)
SG (1) SG11201810934TA (https=)
WO (1) WO2017212249A1 (https=)
ZA (1) ZA201807852B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
EP3572068A1 (en) * 2018-05-22 2019-11-27 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. New salt of cysteamine for the preparation of highly respirable particles
EP3866775B1 (en) * 2018-10-17 2025-03-19 Novabiotics Limited Cysteamine for use in the treatment of lung diseases
BR112023002988A2 (pt) * 2020-09-03 2023-04-04 Philip Morris Products Sa Composições em pó ativas de baixa higroscopicidade secas por pulverização
BR112023001929A2 (pt) 2020-09-03 2023-03-14 Philip Morris Products Sa Composições em pó ativas de baixa higroscopicidade
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
EP4444323A4 (en) * 2021-12-07 2025-12-03 Cila Therapeutic Inc ANTIVIRAL THERAPEUTIC AGENTS AND THEIR USES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054574A1 (en) * 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8901570D0 (sv) * 1989-05-02 1989-05-02 Draco Ab Organic salts of cysteine derivatives
JP4744533B2 (ja) 2004-12-30 2011-08-10 ドゥビエル カンパニー リミテッド 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
WO2008077712A1 (en) 2006-12-22 2008-07-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
CN101342155B (zh) * 2007-07-11 2012-01-04 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
CA2744655A1 (en) * 2008-11-27 2010-06-03 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
CN102341105B (zh) * 2009-02-03 2014-09-17 微生物公司 用作上皮组织、急性和慢性伤口、细菌生物被膜和其他适应症的抗菌剂的铋硫醇
WO2010138419A2 (en) 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
EP2709646A4 (en) 2011-05-19 2015-05-13 Savara Inc DRY POWDER VANCOMYCIN COMPOSITIONS AND RELATED METHODS
JP5981123B2 (ja) 2011-10-11 2016-08-31 サンサ コーポレーション （バルバドス） インク ニコチン薬の製造法およびその方法により製造される医薬
WO2013062544A1 (en) * 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
JP2015509489A (ja) * 2012-02-10 2015-03-30 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ がんの処置のためのグリシン開裂系の阻害
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
GB201416716D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054574A1 (en) * 2013-10-11 2015-04-16 Zisman Lawrence S Spray dry formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B. Buchan, FORMULATION STUDIES ON CYSTEAMINE FOR THE TREATMENT OF NEPHROPATHIC CYSTINOSIS, Robert Gordon University, 2011, pp. 1-223

Also Published As

Publication number Publication date
EP3463325B1 (en) 2023-11-08
FI3463325T3 (fi) 2023-12-19
RU2018142841A3 (https=) 2020-09-30
CA3026743C (en) 2024-05-28
JP7195934B2 (ja) 2022-12-26
WO2017212249A1 (en) 2017-12-14
AU2017277897B2 (en) 2022-09-08
BR112018075221B1 (pt) 2024-02-06
CA3096121C (en) 2022-11-15
CA3026743A1 (en) 2017-12-14
US20190175501A1 (en) 2019-06-13
RU2018142841A (ru) 2020-06-04
KR20190016957A (ko) 2019-02-19
NZ748596A (en) 2025-06-27
BR112018075221A2 (pt) 2019-03-19
JP2019517541A (ja) 2019-06-24
CN109310654A (zh) 2019-02-05
CA3096121A1 (en) 2017-12-14
ZA201807852B (en) 2023-05-31
MX2018014278A (es) 2019-03-14
AU2017277897A1 (en) 2018-12-20
EP3463325A1 (en) 2019-04-10
GB201609940D0 (en) 2016-07-20
US11369568B2 (en) 2022-06-28
SG11201810934TA (en) 2019-01-30
DK3463325T3 (da) 2024-01-02
ES2965017T3 (es) 2024-04-10

Similar Documents

Publication Publication Date Title
KR102412212B1 (ko) 황-함유 화합물을 포함하는 마이크로입자
US10905660B2 (en) Microparticles
CA2468958C (en) Pulmonary delivery of aminoglycosides
CA2981038C (en) Dry powder vancomycin compositions and associated methods
BR112013007304B1 (pt) Pós secos de cátion de metal monovalente para inalação
Manniello et al. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility
JP2012522009A (ja) 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
CN102448439A (zh) 用于改变黏膜内衬的生物物理特性的柠檬酸钙及乳酸钙调配物
PT1594500E (pt) Tratamento para doenças bacterianas dos órgãos respiratórios por aplicação local de fluoroquinolonas
US9572774B2 (en) Dry powder vancomycin compositions and associated methods
Saha et al. Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections
RU2780397C2 (ru) Микрочастицы, содержащие серосодержащие соединения
ES2918193T3 (es) Polvo medicamentoso para administración por inhalación y un proceso del mismo
WO2006033713A2 (en) Methods for ciprofloxacin inhalation
IL263540B2 (en) Microparticles that include a sulfur-containing compound
AU2002361897B2 (en) Pulmonary delivery of aminoglycosides
Manniello Drug delivery to the lung in Cystic Fibrosis: deposition, dissolution, mucus interaction and microbiological evaluation of dry powder inhalers
Gadgil A comparative study between high potency dry powder inhalation and nebulized solution of vancomycin hydrochloride for lung delivery

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000